Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

"#1 prescribed" claim must be dropped from Zantac 75 package insert -- FDA.

This article was originally published in The Tan Sheet

Executive Summary

ZANTAC 75 "#1 PRESCRIBED" CLAIM MUST BE DROPPED FROM PACKAGE INSERT, FDA said in its Dec. 19 approval letter to Glaxo Well-come. As one of four revisions to proposed labeling requested by the agency, the letter instructs Glaxo Wellcome to "delete the statement `Since 1988, the medicine in Zantac 75 has been the #1 prescribed acid reducer'" from the package insert. The Rx-to-OTC switch product will be marketed by Warner-Lambert under a joint-venture arrangement with Glaxo Wellcome.

Topics

UsernamePublicRestriction

Register

PS084618

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel